{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T17:43:53Z","timestamp":1789494233318,"version":"build-2803163510"},"reference-count":19,"publisher":"Oxford University Press (OUP)","issue":"Supplement_1","license":[{"start":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T00:00:00Z","timestamp":1739923200000},"content-version":"vor","delay-in-days":18,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,2,19]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Sodium-glucose cotransporter 2 inhibitors (SGLT2i) have been shown to reduce cardiovascular (CV) mortality and heart failure (HF) hospitalizations, independently from left ventricular ejection fraction (EF). Their efficacy has been assessed both in patients with reduced and preserved EF, with notable benefits in renal outcomes as well. The initiation of SGLT2i in the early phase of hospitalization for acute HF has proven to be safe and beneficial. The EMPULSE and DICTATE-AHF trials support early empagliflozin and dapagliflozin use, respectively, reducing worsening HF events, improving quality of life, and enhancing diuretic efficiency. Notably, these benefits emerge shortly after the initiation of therapy, underscoring the importance of early integration into guideline-directed medical therapy (GDMT). Despite concerns regarding deterioration of renal function, SGLT2i appear to be safe even in patients with low estimated glomerular filtration rates (eGFR). Data suggest that SGLT2i benefits persist without increased safety risks, reassuring clinicians of their efficacy in patients experiencing renal decline. Concerns about volume depletion induced by SGLT2i have also been addressed, with documented enhanced diuresis without adverse renal impacts. Moreover, SGLT2i have been associated with a lower risk of hyperkalaemia events, thus allowing for better optimization of GDMT, including the use of mineralocorticoid receptor antagonists. Overall, these findings highlight the broad CV, renal, and metabolic benefits of SGLT2i, advocating for their early and widespread use in HF management, regardless of EF or eGFR.<\/jats:p>","DOI":"10.1093\/eurheartjsupp\/suae117","type":"journal-article","created":{"date-parts":[[2024,12,22]],"date-time":"2024-12-22T20:20:43Z","timestamp":1734898843000},"page":"i137-i140","source":"Crossref","is-referenced-by-count":11,"title":["SGLT2 inhibitors and new frontiers in heart failure treatment regardless of ejection fraction and setting"],"prefix":"10.1093","volume":"27","author":[{"given":"Anna","family":"Merlo","sequence":"first","affiliation":[{"name":"Cardiovascular Department, Papa Giovanni XXIII Hospital , Piazza OMS 1, 24127 Bergamo ,","place":["Italy"]},{"name":"University of Milano-Bicocca , Piazza dell'Ateneo Nuovo 1, 20126 Milano ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6682-0074","authenticated-orcid":false,"given":"Emilia","family":"D\u2019Elia","sequence":"additional","affiliation":[{"name":"Cardiovascular Department, Papa Giovanni XXIII Hospital , Piazza OMS 1, 24127 Bergamo ,","place":["Italy"]},{"name":"University of Milano-Bicocca , Piazza dell'Ateneo Nuovo 1, 20126 Milano ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Di Odoardo","sequence":"additional","affiliation":[{"name":"Cardiovascular Department, Papa Giovanni XXIII Hospital , Piazza OMS 1, 24127 Bergamo ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edoardo","family":"Sciatti","sequence":"additional","affiliation":[{"name":"Cardiovascular Department, Papa Giovanni XXIII Hospital , Piazza OMS 1, 24127 Bergamo ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Senni","sequence":"additional","affiliation":[{"name":"Cardiovascular Department, Papa Giovanni XXIII Hospital , Piazza OMS 1, 24127 Bergamo ,","place":["Italy"]},{"name":"University of Milano-Bicocca , Piazza dell'Ateneo Nuovo 1, 20126 Milano ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,2,19]]},"reference":[{"key":"2025021911183365000_suae117-B1","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med"},{"key":"2025021911183365000_suae117-B2","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"key":"2025021911183365000_suae117-B3","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction","volume":"387","author":"Solomon","year":"2022","journal-title":"N Engl J Med"},{"key":"2025021911183365000_suae117-B4","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"key":"2025021911183365000_suae117-B5","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1093\/eurheartj\/ehab798","article-title":"Effect of empagliflozin in patients with heart failure across the spectrum of left ventricular ejection fraction","volume":"43","author":"Butler","year":"2022","journal-title":"Eur Heart J"},{"key":"2025021911183365000_suae117-B6","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/S0140-6736(20)31824-9","article-title":"SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials","volume":"396","author":"Zannad","year":"2020","journal-title":"Lancet"},{"key":"2025021911183365000_suae117-B7","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1001\/jamacardio.2022.4210","article-title":"Dapagliflozin and kidney outcomes in patients with heart failure with mildly reduced or preserved ejection fraction: a prespecified analysis of the DELIVER randomized clinical trial","volume":"8","author":"Mc Causland","year":"2023","journal-title":"JAMA Cardiol"},{"key":"2025021911183365000_suae117-B8","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1002\/ejhf.2857","article-title":"Cardiac and kidney benefits of empagliflozin in heart failure across the spectrum of kidney function: insights from the EMPEROR-Preserved trial","volume":"25","author":"Sharma","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"2025021911183365000_suae117-B9","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1002\/ejhf.2420","article-title":"Early benefit with empagliflozin in heart failure with preserved ejection fraction: insights from the EMPEROR-Preserved trial","volume":"24","author":"Butler","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"2025021911183365000_suae117-B10","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1002\/ejhf.1713","article-title":"Randomized, double-blind, placebo-controlled, multicentre pilot study on the effects of empagliflozin on clinical outcomes in patients with acute decompensated heart failure (EMPA-RESPONSE-AHF)","volume":"22","author":"Damman","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2025021911183365000_suae117-B11","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/s41591-021-01659-1","article-title":"The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial","volume":"28","author":"Voors","year":"2022","journal-title":"Nat Med"},{"key":"2025021911183365000_suae117-B12","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1016\/j.jacc.2024.02.009","article-title":"Efficacy and safety of dapagliflozin in patients with acute heart failure","volume":"83","author":"Cox","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"2025021911183365000_suae117-B13","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1016\/j.jacc.2023.09.797","article-title":"SGLT2i and deterioration of kidney function in heart failure: another demonstration for tolerance of \u201chypercreatininemia\u201d","volume":"82","author":"Coca","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"2025021911183365000_suae117-B14","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1016\/j.jacc.2023.08.026","article-title":"Dapagliflozin in patients with heart failure and deterioration in renal function","volume":"82","author":"Chatur","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"2025021911183365000_suae117-B15","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1161\/CIRCULATIONAHA.122.059038","article-title":"Effects of early empagliflozin initiation on diuresis and kidney function in patients with acute decompensated heart failure (EMPAG-HF)","volume":"146","author":"Schulze","year":"2022","journal-title":"Circulation"},{"key":"2025021911183365000_suae117-B16","doi-asserted-by":"crossref","first-page":"2984","DOI":"10.1093\/eurheartj\/ehac306","article-title":"Empagliflozin and serum potassium in heart failure: an analysis from EMPEROR-Pooled","volume":"43","author":"Ferreira","year":"2022","journal-title":"Eur Heart J"},{"key":"2025021911183365000_suae117-B17","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/j.jacc.2024.05.080","article-title":"Enabling medical therapy for heart failure: new tools bring a new reality for hyperkalemia","volume":"84","author":"Greene","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"2025021911183365000_suae117-B18","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s11906-024-01314-3","article-title":"Is there a role for SGLT2 inhibitors in patients with end-stage kidney disease?","volume":"26","author":"Siddiqui","year":"2024","journal-title":"Curr Hypertens Rep"},{"key":"2025021911183365000_suae117-B19","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1016\/j.jacc.2024.03.429","article-title":"SGLT2 inhibitor therapy in patients with transthyretin amyloid cardiomyopathy","volume":"83","author":"Porcari","year":"2024","journal-title":"J Am Coll Cardiol"}],"container-title":["European Heart Journal Supplements"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurheartjsupp\/article-pdf\/27\/Supplement_1\/i137\/61968559\/suae117.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartjsupp\/article-pdf\/27\/Supplement_1\/i137\/61968559\/suae117.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T11:18:57Z","timestamp":1739963937000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartjsupp\/article\/27\/Supplement_1\/i137\/8023329"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":19,"journal-issue":{"issue":"Supplement_1","published-online":{"date-parts":[[2025,2,19]]},"published-print":{"date-parts":[[2025,2,19]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartjsupp\/suae117","relation":{},"ISSN":["1520-765X","1554-2815"],"issn-type":[{"value":"1520-765X","type":"print"},{"value":"1554-2815","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,2]]},"published":{"date-parts":[[2025,2]]}}}